Investing.com - GlycoMimetics (NASDAQ: GLYC) reported second quarter EPS of $-0.130, $0.05 better than the analyst estimate of $-0.180. Revenue for the quarter came in at $50K...
Investing.com - GlycoMimetics (NASDAQ: GLYC) reported first quarter EPS of $-0.170, $0.01 worse than the analyst estimate of $-0.160. Revenue for the quarter came in at $0.00...
Investing.com - GlycoMimetics (NASDAQ: GLYC) reported first quarter EPS of $-0.190, $0.02 worse than the analyst estimate of $-0.170. Revenue for the quarter came in at $10.2M...
Investing.com - GlycoMimetics (NASDAQ:GLYC) reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that was in line with...
GlycoMimetics (NASDAQ:GLYC) reported Q1 EPS of ($0.28), $0.03 better than the analyst estimate of ($0.31). Cash and cash equivalents at March 31, 2022 were $76.5 million. For...
GlycoMimetics, Inc. (Nasdaq: NASDAQ:GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases,...
Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Consumer Services, Industrials and Consumer Goods sectors led shares higher. At the close in...